FDA Looking For Other Primary Endpoints In CHF Trials For ICDs, Pacers
This article was originally published in The Gray Sheet
Executive Summary
Peak VO2 levels will be considered a viable primary endpoint by FDA in reviewing ICDs and pacemakers for congestive heart failure
You may also be interested in...
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
FDA, Advisory Panel Agree: Post-Hoc Analyses Won't Fly
CDRH's critique of Guidant's post-hoc analysis of its Contak CD data sends a clear warning to sponsors who attempt to draw positive conclusions about one subgroup from an inconclusive clinical trial.